{"id":"W3107922790","doi":"10.1016/j.pan.2020.10.008","title":"Organoid Personalized Therapeutics and the Pancreatic Adenocarcinoma Signature Stratification for treatment (PASS) – 01 trial","year":2020,"lang":"en","type":"article","venue":"Pancreatology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; FOLFIRINOX; Oncology; Pancreatic cancer; Internal medicine; Gemcitabine; Chemotherapy; Biomarker; Progression-free survival; Transcriptome; Erlotinib; Cancer; Irinotecan; Colorectal cancer; Gene; Gene expression","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003227918,0.0002539352,0.001116145,0.00005080105,0.0002272517,0.00002640801,0.0001250419,0.0002844873,0.0001696315],"category_scores_gemma":[0.0004128561,0.000147241,0.0001713063,0.0001695561,0.0006980956,0.00003485879,0.00002693048,0.0001877104,0.00002522461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008815794,"about_ca_system_score_gemma":0.0004183359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005154524,"about_ca_topic_score_gemma":0.00001294212,"domain_scores_codex":[0.9982508,0.0003711007,0.0003454178,0.0004453909,0.0001943924,0.0003929138],"domain_scores_gemma":[0.9976806,0.00153811,0.0001363013,0.0003111308,0.0001235262,0.0002102999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6499079,0.001086926,0.2010803,0.0006479239,0.005595118,0.000157142,0.01611095,0.000001035696,0.01890745,0.0869149,0.005097828,0.01449242],"study_design_scores_gemma":[0.8070186,0.02524053,0.04874811,0.00008895707,0.01778219,0.0009717733,0.005794252,0.02322379,0.004644388,0.00637169,0.05921464,0.0009011065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9110083,0.008597969,0.002092507,0.07131466,0.00009843673,0.005069654,0.00003703632,0.00008837023,0.00169307],"genre_scores_gemma":[0.9908848,0.001377071,0.002046399,0.002855275,0.0004693701,0.0009248965,0.0001040377,0.00003477481,0.001303323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1571106,"threshold_uncertainty_score":0.6004316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07600460637495861,"score_gpt":0.3475347002636003,"score_spread":0.2715300938886417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}